The role of preoperative serum thyroglobulin in the diagnosis and treatment of differentiated thyroid cancer: a systematic review and meta-analysis.

IF 3.5 3区 医学 Q2 ONCOLOGY
Frontiers in Oncology Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1426785
Ying Lu, Hao Zhao, ChunHao Liu, ZiFeng Kuang, XiaoYi Li
{"title":"The role of preoperative serum thyroglobulin in the diagnosis and treatment of differentiated thyroid cancer: a systematic review and meta-analysis.","authors":"Ying Lu, Hao Zhao, ChunHao Liu, ZiFeng Kuang, XiaoYi Li","doi":"10.3389/fonc.2024.1426785","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Serum thyroglobulin (Tg) is a critical marker for monitoring tumor recurrence and metastasis in patients who have undergone total thyroidectomy for differentiated thyroid cancer (DTC). While the definitive role of preoperative serum Tg in DTC is not yet established, studies suggest its importance in differentiating between benign and malignant thyroid nodules with indeterminate cytology, as well as in predicting distant metastasis (DM) in patients with DTC.</p><p><strong>Methods: </strong>A thorough literature review was conducted on the use of preoperative serum Tg in differentiating between benign and malignant thyroid nodules, and in evaluating the extent of DTC lesions. Relevant studies were systematically searched in PubMed, Embase, Cochrane, Scopus, and ClinicalTrials databases. A meta-analysis was performed on studies where the ratios between serum Tg diagnostic thresholds and the upper limit of the reference range were similar.</p><p><strong>Results: </strong>Recent studies showed significantly elevated preoperative serum Tg levels in patients with DTC compared with normal individuals. However, there are inconsistencies in the serum Tg levels between patients with preoperative DTC and benign thyroid nodules across different studies. In patients with thyroid nodules who had indeterminate cytology (negative Tg antibody), the preoperative serum Tg levels were significantly higher in malignant nodules than in benign ones (meta-analysis: odds ratio: 2.59, 95% confidence intervals: 1.59-4.21, P = 0.0001). Although the meta-analysis indicated that high preoperative serum Tg is a risk factor for central lymph node metastasis in patients with DTC (meta-analysis: odds ratio: 1.68, 95% confidence interval: 1.32-2.14, P < 0.0001), some studies suggest that high preoperative serum Tg in patients with DTC does not necessarily lead to central lymph node metastasis. Furthermore, preoperative serum Tg might possess a suggestive value regarding the likelihood of DTC patients developing DM.</p><p><strong>Conclusion: </strong>Preoperative serum Tg shows promise in differentiating between benign and malignant nodules in thyroid nodule patients with indeterminate cytology. However, further research is necessary to determine its predictive significance for lymph node metastasis and DM in patients with DTC.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42024472074.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1426785"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703863/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1426785","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Serum thyroglobulin (Tg) is a critical marker for monitoring tumor recurrence and metastasis in patients who have undergone total thyroidectomy for differentiated thyroid cancer (DTC). While the definitive role of preoperative serum Tg in DTC is not yet established, studies suggest its importance in differentiating between benign and malignant thyroid nodules with indeterminate cytology, as well as in predicting distant metastasis (DM) in patients with DTC.

Methods: A thorough literature review was conducted on the use of preoperative serum Tg in differentiating between benign and malignant thyroid nodules, and in evaluating the extent of DTC lesions. Relevant studies were systematically searched in PubMed, Embase, Cochrane, Scopus, and ClinicalTrials databases. A meta-analysis was performed on studies where the ratios between serum Tg diagnostic thresholds and the upper limit of the reference range were similar.

Results: Recent studies showed significantly elevated preoperative serum Tg levels in patients with DTC compared with normal individuals. However, there are inconsistencies in the serum Tg levels between patients with preoperative DTC and benign thyroid nodules across different studies. In patients with thyroid nodules who had indeterminate cytology (negative Tg antibody), the preoperative serum Tg levels were significantly higher in malignant nodules than in benign ones (meta-analysis: odds ratio: 2.59, 95% confidence intervals: 1.59-4.21, P = 0.0001). Although the meta-analysis indicated that high preoperative serum Tg is a risk factor for central lymph node metastasis in patients with DTC (meta-analysis: odds ratio: 1.68, 95% confidence interval: 1.32-2.14, P < 0.0001), some studies suggest that high preoperative serum Tg in patients with DTC does not necessarily lead to central lymph node metastasis. Furthermore, preoperative serum Tg might possess a suggestive value regarding the likelihood of DTC patients developing DM.

Conclusion: Preoperative serum Tg shows promise in differentiating between benign and malignant nodules in thyroid nodule patients with indeterminate cytology. However, further research is necessary to determine its predictive significance for lymph node metastasis and DM in patients with DTC.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42024472074.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Oncology
Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
6.20
自引率
10.60%
发文量
6641
审稿时长
14 weeks
期刊介绍: Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信